There was no significant difference in the medication cost
between intervention and control groups. Nor was there a
significant change from baseline to endpoint. This does not
mean that the pharmacist achieved no financial savings. More
drugs were stopped in the intervention group, but such savings
were eclipsed by the additional cost of new medicines
added. The savings were therefore recycled to address new
therapeutic issues, turning a cost-benefit into an opportunitybenefit
with no increase in the overall cost